Analyzing Valeant’s Quarterly Earnings and Estimates
Valeant Pharmaceuticals (VRX) reported a GAAP net loss of ~$2.7 billion during the first quarter—compared to the GAAP net income of ~$628 million during the first quarter of 2017. Also, the GAAP EPS was negative at -$7.68. The company reported a loss during the first quarter—compared to the GAAP EPS of $1.79 during the first quarter of 2017.